Please sign in to follow a disease.
A simple phone call may help millions with diabetes manage insulin — a trial puts it to the test
NCT ID NCT07729501
First seen Jul 27, 2026 · Last updated Sep 16, 2026 · Updated 4 times
Summary
This trial tests whether a multilingual interactive voice response (IVR) system can help adults with type 2 diabetes and low health literacy adjust their insulin doses. Participants use a feature phone to report blood sugar levels and receive algorithm-guided dose recommendations, reviewed by clinical staff. The study compares this approach to standard clinic-based insulin titration over 12 weeks, measuring changes in blood sugar control.
What this could mean
Our plain-language read of the trial. This is informational only, not medical advice or a prediction.
- Active substance
- multilingual interactive voice response (IVR) system for insulin dose adjustment
- What this could lead to
- If it works, this could offer a simple, phone-based way for people with low health literacy to manage insulin dosing at home, improving blood sugar control.
- What could go wrong
- The trial is small (220 participants) and short (12 weeks), so results may not apply to broader populations or longer-term outcomes. The system still requires human review, so it is not fully automated.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Phase
-
Not a phased trial
Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.
- Participants
-
About 220 people
The number the study aims to enrol. It can still change while the study runs.
- Started
-
Sep 2026
- Expected to finish
-
Mar 2027
An estimate. End dates often move.
- Lead sponsor
-
Other sponsor
The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
- Ages
-
18 years and older
- Sex
-
Anyone
- Healthy volunteers
-
Not accepted
This study is not open to healthy volunteers. The entry requirements below say who it is open to.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: * Age 18 years or older. * Diagnosed with type 2 diabetes mellitus. * Currently receiving basal insulin or considered by the treating clinician to require initiation or adjustment of basal insulin. * Glycemic control considered inadequate and requiring basal insulin titration according to the study protocol. * Low health literacy as determined using the study-approved screening method. * Able to communicate in one of the languages supported by the study intervention. * Has access to a functioning feature phone or mobile telephone and is able to receive automated voice calls. * Able and willing to perform fasting blood glucose monitoring according to the study procedures. * Willing and able to provide informed consent. * Willing to comply with study procedures and complete the 12-week follow-up. Exclusion Criteria: * Type 1 diabetes mellitus, gestational diabetes, or another specific form of diabetes other than type 2 diabetes mellitus. * Pregnancy, current breastfeeding, or planned pregnancy during the study period. * Current use of an insulin pump. * Severe hypoglycemia requiring assistance from another person within the period specified in the protocol before enrollment. * Recurrent hypoglycemia or another clinical condition that, in the investigator's judgment, makes protocol-directed insulin titration unsafe. * Acute metabolic decompensation, including diabetic ketoacidosis or hyperosmolar hyperglycemic state, at screening or within the period specified in the protocol. * Severe renal, hepatic, cardiac, psychiatric, cognitive, hearing, or other medical impairment that would prevent safe participation or completion of the voice-call intervention. * Inability to understand or respond to the study's supported voice-call languages. * Inability to use the telephone or glucose-monitoring procedures, with or without assistance permitted by the protocol. * Current participation in another interventional clinical trial that could interfere with the study outcomes. * Any other condition that, in the investigator's judgment, would make participation unsafe or compromise adherence to the study procedures.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Hyperglycemia due to type 2 diabetes mellitus are added.
Genom att skicka in godkänner du våra Användarvillkor
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Shifa Hospital
Lahore, Pakistan
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Four pills, one goal: can a new combo tame type 2 diabetes?
- Can banding the gut tame type 2 diabetes?
- Can QR codes and videos teach better foot care?
- Which insulin dosing method keeps hospital blood sugar in check?
- Can a new injection help tackle obesity? a trial puts MWN105 to the test
- Can when you eat change how a diabetes drug works?